{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:29:04Z","timestamp":1791599344794,"version":"4.3.4"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1038\/s41569-018-0107-8","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T11:41:59Z","timestamp":1542022919000},"page":"155-165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":334,"title":["PCSK9 inhibitors: clinical evidence and implementation"],"prefix":"10.1038","volume":"16","author":[{"given":"Marc S.","family":"Sabatine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,12]]},"reference":[{"key":"107_CR1","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1086\/302370","volume":"64","author":"M Varret","year":"1999","unstructured":"Varret, M. et al. A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Am. J. Hum. Genet. 64, 1378\u20131387 (1999).","journal-title":"Am. J. Hum. Genet."},{"key":"107_CR2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel, M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat.\u00a0Genet. 34, 154\u2013156 (2003).","journal-title":"Nat. Genet."},{"key":"107_CR3","doi-asserted-by":"publisher","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","volume":"50","author":"JD Horton","year":"2009","unstructured":"Horton, J. D., Cohen, J. C. & Hobbs, H. H. PCSK9: a convertase that coordinates LDL catabolism. J. Lipid Res. 50, S172\u2013S177 (2009).","journal-title":"J. Lipid Res."},{"key":"107_CR4","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1073\/pnas.0402133101","volume":"101","author":"KN Maxwell","year":"2004","unstructured":"Maxwell, K. N. & Breslow, J. L. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl Acad. Sci. USA 101, 7100\u20137105 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"107_CR5","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1073\/pnas.0409736102","volume":"102","author":"KN Maxwell","year":"2005","unstructured":"Maxwell, K. N., Fisher, E. A. & Breslow, J. L. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc. Natl Acad. Sci. USA 102, 2069\u20132074 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"107_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng1509","volume":"37","author":"J Cohen","year":"2005","unstructured":"Cohen, J. et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37, 161\u2013165 (2005).","journal-title":"Nat. Genet."},{"key":"107_CR7","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen, J. C. et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264\u20131272 (2006).","journal-title":"N. Engl. J. Med."},{"key":"107_CR8","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1056\/NEJMc0707445","volume":"358","author":"S Kathiresan","year":"2008","unstructured":"Kathiresan, S. & Myocardial Infarction Genetics, C. A. PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction. N. Engl. J.\u00a0Med. 358, 2299\u20132300 (2008).","journal-title":"N. Engl. J. Med."},{"key":"107_CR9","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","volume":"375","author":"BA Ference","year":"2016","unstructured":"Ference, B. A. et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N. Engl. J. Med. 375, 2144\u20132153 (2016).","journal-title":"N. Engl. J. Med."},{"key":"107_CR10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1177\/1074248418774043","volume":"23","author":"S Wasserman","year":"2018","unstructured":"Wasserman, S. et al. Comparison of LDL-C reduction using different evolocumab doses and intervals: biological insights and treatment implications. J. Cardiovasc. Pharmacol. Ther. 23, 423\u2013432 (2018).","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"107_CR11","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","volume":"63","author":"MJ Koren","year":"2014","unstructured":"Koren, M. J. et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J. Am. Coll. Cardiol. 63, 2531\u20132540 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"107_CR12","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1001\/jama.2014.4030","volume":"311","author":"JG Robinson","year":"2014","unstructured":"Robinson, J. G. et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 311, 1870\u20131882 (2014).","journal-title":"JAMA"},{"key":"107_CR13","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","volume":"63","author":"E Stroes","year":"2014","unstructured":"Stroes, E. et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J. Am. Coll. Cardiol. 63, 2541\u20132548 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"107_CR14","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2016.3608","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen, S. E. et al. Efficacy and tolerability of evolocumab versus ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA 315, 1580\u20131590 (2016).","journal-title":"JAMA"},{"key":"107_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal, F. J. et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a\u00a0randomised, double-blind, placebo-controlled trial. Lancet 385, 331\u2013340 (2015).","journal-title":"Lancet"},{"key":"107_CR16","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","volume":"35","author":"EA Stein","year":"2014","unstructured":"Stein, E. A. et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur. Heart J. 35, 2249\u20132259 (2014).","journal-title":"Eur. Heart J."},{"key":"107_CR17","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1001\/jamacardio.2016.5395","volume":"2","author":"NR Desai","year":"2017","unstructured":"Desai, N. R. et al. Association between circulating baseline proprotein convertase subtilisin kexin type 9 levels and efficacy of evolocumab. JAMA Cardiol. 2, 556\u2013560 (2017).","journal-title":"JAMA Cardiol."},{"key":"107_CR18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal, F. J. et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trial. Lancet 385, 341\u2013350 (2015).","journal-title":"Lancet"},{"key":"107_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","volume":"5","author":"FJ Raal","year":"2017","unstructured":"Raal, F. J. et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 5, 280\u2013290 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"107_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","volume":"176","author":"EM Roth","year":"2014","unstructured":"Roth, E. M. et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial. Int. J. Cardiol. 176, 55\u201361 (2014).","journal-title":"Int. J. Cardiol."},{"key":"107_CR21","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","volume":"169","author":"DJ Kereiakes","year":"2015","unstructured":"Kereiakes, D. J. et al. Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am. Heart J. 169, 906\u2013915.e13 (2015).","journal-title":"Am. Heart J."},{"key":"107_CR22","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","volume":"36","author":"CP Cannon","year":"2015","unstructured":"Cannon, C. P. et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur. Heart J. 36, 1186\u20131194 (2015).","journal-title":"Eur. Heart J."},{"key":"107_CR23","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","volume":"9","author":"PM Moriarty","year":"2015","unstructured":"Moriarty, P. M. et al. Efficacy and safety of alirocumab versus ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J. Clin. Lipidol. 9, 758\u2013769 (2015).","journal-title":"J. Clin. Lipidol."},{"key":"107_CR24","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson, J. G. et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1489\u20131499 (2015).","journal-title":"N. Engl. J. Med."},{"key":"107_CR25","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.atherosclerosis.2016.08.043","volume":"254","author":"EM Roth","year":"2016","unstructured":"Roth, E. M. et al. A phase III randomized trial evaluating alirocumab 300\u2005mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. Atherosclerosis 254, 254\u2013262 (2016).","journal-title":"Atherosclerosis"},{"key":"107_CR26","first-page":"2996","volume":"36","author":"JJ Kastelein","year":"2015","unstructured":"Kastelein, J. J. et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur.\u00a0Heart J. 36, 2996\u20133003 (2015).","journal-title":"Eur. Heart J."},{"key":"107_CR27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","volume":"30","author":"HN Ginsberg","year":"2016","unstructured":"Ginsberg, H. N. et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160\u2005mg\/dl or higher. Cardiovasc. Drugs Ther. 30, 473\u2013483 (2016).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"107_CR28","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacl.2017.12.008","volume":"12","author":"ML Hartgers","year":"2018","unstructured":"Hartgers, M. L. et al. Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia. J. Clin. Lipidol. 12, 390\u2013396.e8 (2018).","journal-title":"J. Clin. Lipidol."},{"key":"107_CR29","unstructured":"US Department of Health & Human Services. Highlights of prescribing information: LIPITOR\u00ae. FDA.gov \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020702s056lbl.pdf\n                    \n                   (2009)."},{"key":"107_CR30","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N.\u00a0Engl. J. Med. 376, 1713\u20131722 (2017).","journal-title":"N. Engl. J. Med."},{"key":"107_CR31","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon, C. P. et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372, 2387\u20132397 (2015).","journal-title":"N. Engl. J. Med."},{"key":"107_CR32","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.113.001969","volume":"128","author":"NR Desai","year":"2013","unstructured":"Desai, N. R. et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy. Circulation 128, 962\u2013969 (2013).","journal-title":"Circulation"},{"key":"107_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.118.034032","volume":"138","author":"EA Bohula","year":"2018","unstructured":"Bohula, E. A. et al. Inflammatory and cholesterol risk in the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in patients with elevated risk). Circulation 138, 131\u2013140 (2018).","journal-title":"Circulation"},{"key":"107_CR34","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ahj.2015.11.015","volume":"173","author":"MS Sabatine","year":"2016","unstructured":"Sabatine, M. S. et al. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. Am. Heart J. 173, 94\u2013101 (2016).","journal-title":"Am. Heart J."},{"key":"107_CR35","doi-asserted-by":"publisher","first-page":"A107","DOI":"10.1016\/S0735-1097(18)30648-X","volume":"71","author":"SD Wiviott","year":"2018","unstructured":"Wiviott, S. D. The effects of adding the CETP inhibitor anacetrapib to statin on urgent and routine revascularization: results from the HPS 3\/TIMI 55-REVEAL trial. J. Am. Coll. Cardiol. 71, A107 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"107_CR36","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins, R. et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388, 2532\u20132561 (2016).","journal-title":"Lancet"},{"key":"107_CR37","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1001\/jamacardio.2017.3944","volume":"2","author":"RP Giugliano","year":"2017","unstructured":"Giugliano, R. P. et al. Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial. JAMA Cardiol. 2, 1385\u20131391 (2017).","journal-title":"JAMA Cardiol."},{"key":"107_CR38","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","volume":"380","author":"PM Ridker","year":"2012","unstructured":"Ridker, P. M., Pradhan, A., MacFadyen, J. G., Libby, P. & Glynn, R. J. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 380, 565\u2013571 (2012).","journal-title":"Lancet"},{"key":"107_CR39","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine, M. S. et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 5, 941\u2013950 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"107_CR40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/clc.22678","volume":"40","author":"RP Giugliano","year":"2017","unstructured":"Giugliano, R. P. et al. Design and rationale of the EBBINGHAUS trial: a phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy \u2014 a cognitive study of patients enrolled in the FOURIER trial. Clin. Cardiol. 40, 59\u201365 (2017).","journal-title":"Clin. Cardiol."},{"key":"107_CR41","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1056\/NEJMoa1701131","volume":"377","author":"RP Giugliano","year":"2017","unstructured":"Giugliano, R. P., Sabatine, M. S. & Ott, B. R. Cognitive function in a randomized trial of evolocumab. N. Engl. J. Med. 377, 1997 (2017).","journal-title":"N. Engl. J. Med."},{"key":"107_CR42","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","volume":"376","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Lipid-reduction variability and antidrug-antibody formation with bococizumab. N. Engl. J. Med. 376, 1517\u20131526 (2017).","journal-title":"N. Engl. J. Med."},{"key":"107_CR43","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ahj.2016.05.010","volume":"178","author":"PM Ridker","year":"2016","unstructured":"Ridker, P. M. et al. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: rationale and design of the studies of PCSK9 inhibition and the reduction of vascular events (SPIRE) lipid lowering and SPIRE cardiovascular outcomes trials. Am. Heart J. 178, 135\u2013144 (2016).","journal-title":"Am. Heart J."},{"key":"107_CR44","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","volume":"376","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N. Engl. J. Med. 376, 1527\u20131539 (2017).","journal-title":"N. Engl. J. Med."},{"key":"107_CR45","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","volume":"168","author":"GG Schwartz","year":"2014","unstructured":"Schwartz, G. G. et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am. Heart J. 168, 682\u2013689 (2014).","journal-title":"Am. Heart J."},{"key":"107_CR46","unstructured":"Schwartz, G. et al. The ODYSSEY OUTCOMES trial: topline results \u2014 alirocumab in patients after acute coronary syndrome. Presented at the 67th Scientific Sessions of the American College of Cardiology (2018)."},{"key":"107_CR47","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1161\/CIRCULATIONAHA.105.586347","volume":"113","author":"SD Wiviott","year":"2006","unstructured":"Wiviott, S. D. et al. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation 113, 1406\u20131414 (2006).","journal-title":"Circulation"},{"key":"107_CR48","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman, M. G. et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 316, 1289\u20131297 (2016).","journal-title":"JAMA"},{"key":"107_CR49","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1093\/eurheartj\/ehx450","volume":"39","author":"BA Ference","year":"2018","unstructured":"Ference, B. A. et al. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Eur. Heart J. 39, 2540\u20132545 (2018).","journal-title":"Eur. Heart J."},{"key":"107_CR50","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks, F. M. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335, 1001\u20131009 (1996).","journal-title":"N. Engl. J. Med."},{"key":"107_CR51","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","volume":"339","author":"Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","year":"1998","unstructured":"Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339, 1349\u20131357 (1998).","journal-title":"N. Engl. J. Med."},{"key":"107_CR52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","unstructured":"Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7\u201322 (2002).","journal-title":"Lancet"},{"key":"107_CR53","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa, J. C. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425\u20131435 (2005).","journal-title":"N. Engl. J. Med."},{"key":"107_CR54","first-page":"1383","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","unstructured":"Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383\u20131389 (1994).","journal-title":"Lancet"},{"key":"107_CR55","first-page":"1217","volume":"377","author":"L Bowman","year":"2017","unstructured":"Hps Timi Reveal Collaborative Group, Bowman, L. et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N. Engl. J. Med. 377, 1217\u20131227 (2017).","journal-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease. N. Engl. J. Med."},{"key":"107_CR56","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","volume":"390","author":"RP Giugliano","year":"2017","unstructured":"Giugliano, R. P. et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet 390, 1962\u20131971 (2017).","journal-title":"Lancet"},{"key":"107_CR57","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jama.2016.11004","volume":"316","author":"DS Kazi","year":"2016","unstructured":"Kazi, D. S. et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA 316, 743\u2013753 (2016).","journal-title":"JAMA"},{"key":"107_CR58","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1001\/jama.2017.9924","volume":"318","author":"DS Kazi","year":"2017","unstructured":"Kazi, D. S. et al. Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial. JAMA 318, 748\u2013750 (2017).","journal-title":"JAMA"},{"key":"107_CR59","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamacardio.2017.2762","volume":"2","author":"GC Fonarow","year":"2017","unstructured":"Fonarow, G. C. et al. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2, 1069\u20131078 (2017).","journal-title":"JAMA Cardiol."},{"key":"107_CR60","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/jamacardio.2017.2293","volume":"2","author":"MS Sabatine","year":"2017","unstructured":"Sabatine, M. S. & Giugliano, R. P. Low-density lipoprotein cholesterol treatment in the proprotein convertase subtilisin\/kexin type 9 inhibitor era: getting back on target. JAMA Cardiol. 2, 935\u2013936 (2017).","journal-title":"JAMA Cardiol."},{"key":"107_CR61","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1001\/jama.2018.2525","volume":"319","author":"EP Navarese","year":"2018","unstructured":"Navarese, E. P. et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 319, 1566\u20131579 (2018).","journal-title":"JAMA"},{"key":"107_CR62","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1001\/jamacardio.2018.2258","volume":"3","author":"MS Sabatine","year":"2018","unstructured":"Sabatine, M. S., Wiviott, S. D., Im, K. A., Murphy, S. A. & Giugliano, R. P. Efficacy and safety of LDL-cholesterol lowering in patient populations starting with low LDL-cholesterol \u2014 a meta-analysis. JAMA Cardiol. 3, 823\u2013828 (2018).","journal-title":"JAMA Cardiol."},{"key":"107_CR63","first-page":"1274","volume":"373","author":"MP Bonaca","year":"2015","unstructured":"Bonaca, M. P., Braunwald, E. & Sabatine, M. S. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 373, 1274\u20131275 (2015).","journal-title":"N. Engl. J. Med."},{"key":"107_CR64","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jacc.2017.07.768","volume":"70","author":"MP Bonaca","year":"2017","unstructured":"Bonaca, M. P. et al. Efficacy and safety of ticagrelor over time in patients with prior MI in PEGASUS-TIMI 54. J. Am. Coll. Cardiol. 70, 1368\u20131375 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"107_CR65","doi-asserted-by":"publisher","first-page":"P3670","DOI":"10.1093\/eurheartj\/ehx504.P3670","volume":"38","author":"M Dellborg","year":"2017","unstructured":"Dellborg, M. et al. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. Eur. Heart J. 38, P3670 (2017).","journal-title":"Eur. Heart J."},{"key":"107_CR66","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jacc.2017.11.050","volume":"71","author":"S Bansilal","year":"2018","unstructured":"Bansilal, S. et al. Ticagrelor for secondary prevention of atherothrombotic events in patients with multivessel coronary disease. J. Am. Coll. Cardiol. 71, 489\u2013496 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"107_CR67","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","volume":"138","author":"MS Sabatine","year":"2018","unstructured":"Sabatine, M. S. et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease: an analysis from FOURIER. Circulation 138, 756\u2013766 (2018).","journal-title":"Circulation"},{"key":"107_CR68","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"MP Bonaca","year":"2018","unstructured":"Bonaca, M. P. et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in\u00a0patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects\u00a0with elevated risk). Circulation 137, 338\u2013350 (2018).","journal-title":"Circulation"},{"key":"107_CR69","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald, K. et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N. Engl. J. Med. 376, 41\u201351 (2017).","journal-title":"N. Engl. J. Med."},{"key":"107_CR70","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray, K. K. et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N.\u00a0Engl. J. Med. 376, 1430\u20131440 (2017).","journal-title":"N. Engl. J. Med."},{"key":"107_CR71","unstructured":"TIMI Study Group. HPS-4\/TIMI 65 ORION-4. TIMI.org\u00a0\n                    http:\/\/www.timi.org\/index.php?page=orion-4\n                    \n                   (2018)."},{"key":"107_CR72","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1093\/eurheartj\/ehx260","volume":"38","author":"C Landlinger","year":"2017","unstructured":"Landlinger, C. et al. The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. Eur.\u00a0Heart J. 38, 2499\u20132507 (2017).","journal-title":"Eur. Heart J."},{"key":"107_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13069-w","volume":"7","author":"Y Pan","year":"2017","unstructured":"Pan, Y. et al. A therapeutic peptide vaccine against PCSK9. Sci. Rep. 7, 12534 (2017).","journal-title":"Sci. Rep."},{"key":"107_CR74","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1161\/ATVBAHA.116.307227","volume":"36","author":"X Wang","year":"2016","unstructured":"Wang, X. et al. CRISPR-Cas9 targeting of PCSK9 in\u00a0human hepatocytes in vivo \u2014 brief report. Arterioscler. Thromb. Vasc. Biol. 36, 783\u2013786 (2016).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"107_CR75","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","volume":"115","author":"Q Ding","year":"2014","unstructured":"Ding, Q. et al. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ. Res. 115, 488\u2013492 (2014).","journal-title":"Circ. Res."},{"key":"107_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04048-4","volume":"9","author":"PI Thakore","year":"2018","unstructured":"Thakore, P. I. et al. RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors. Nat. Commun. 9, 1674\u00a0(2018).","journal-title":"Nat. Commun."},{"key":"107_CR77","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170\u2005000 participants in 26 randomised trials. Lancet 376, 1670\u20131681 (2010).","journal-title":"Lancet"}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41569-018-0107-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41569-018-0107-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41569-018-0107-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:22:29Z","timestamp":1684606949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-018-0107-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,12]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["107"],"URL":"https:\/\/doi.org\/10.1038\/s41569-018-0107-8","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,12]]},"assertion":[{"value":"12 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S. received research grant support through Brigham and Women\u2019s Hospital, Boston, USA, from Amgen, AstraZeneca, Daiichi-Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen Research and Development, MedImmune, Merck, Novartis, Pfizer, Poxel, Takeda and The Medicines Company. M.S. also consulted for Amgen, AstraZeneca, Bristol-Myers Squibb, CVS Caremark, Esperion, Intarcia, Janssen Research and Development, MedImmune, Merck, Novartis and The Medicines Company.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}